Semler Scientific, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023
July 11, 2023 at 08:03 am EDT
Share
Semler Scientific, Inc. provided revenue guidance for the second quarter ending June 30, 2023 . The company expects its revenues for the second quarter ending June 30, 2023 will be the highest quarterly revenues in its history, driven by continued sales of QuantaFlo® to existing and new customers to test for peripheral arterial disease.
Semler Scientific, Inc. develops, manufactures, and markets products and services that assist in evaluating and treating chronic diseases. The Company provides technology solutions to healthcare providers. The Company's flagship product, QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patientâs vascular condition, including assessments of patients who have vascular disease. QuantaFlo features a sensor clamp that is placed on the toe or finger. Infrared light emitted from the clamp on the dorsal surface of the digit is scattered and reflected by the red blood cells coursing through the area of illumination. Returning light is sensed by the sensor. A blood flow waveform is instantaneously constructed by its proprietary software algorithm. Its customers for QuantaFlo include insurance plans, physician groups, risk assessment groups, hospitals and retailers.
SEMLER SCIENTIFIC, INC. 
